HBV Mutation Detail Information

> I169T Search Result

Mutation Information

Mutation Site	I169T
Mutation Type	Amino acid level
Gene/Protein/Region Type	RT
Genotype/Subtype	D
Relevant Drug	lamivudine (LAM)

Literature Information

PubMed PMID	15328117
Disease	Chronic hepatitis B
Published Year	2004
Journal	Antimicrobial agents and chemotherapy
Title	Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.
Author	Tenney DJ,Levine SM,Rose RE,Walsh AW,Weinheimer SP,Discotto L,Plym M,Pokornowski K,Yu CF,Angus P,Ayres A,Bartholomeusz A,Sievert W,Thompson G,Warner N,Locarnini S,Colonno RJ
Evidence	Viral rebound occurred after 76 weeks of therapy with ETV at 1.0 mg, with the emergence of rtT184G, rtI169T, and rtS202I substitutions within the preexisting 3TC(r) background.

Contents
Description

Mutation Information Note

Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)

Literature Information Note

Evidence: sentence contains this mutation information in the citation